DRI Healthcare Trust is cashing out of its royalty investment in the drug Ekterly for about $178 million.
The Toronto-based pharmaceutical royalty company said Friday that it exercised its contractual put option in connection with the completion of Chiesi Group's acquisition of KalVista Pharmaceuticals.
A put option gives the holder the right, but not the obligation, to sell an asset back to the issuer at a specified price, which in this case DRI exercised.
The company expects to receive the payment no later than mid-August, it said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
July 10, 2026 09:46 ET (13:46 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.